PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid

The cardiovascular benefits of fibrates have been shown to be heterogeneous and to depend on the presence of atherogenic dyslipidemia. We investigated whether genetic variability in the PPARA gene, coding for the pharmacological target of fibrates (PPAR-α), could be used to improve the selection of...

Descripción completa

Detalles Bibliográficos
Autores principales: Morieri, Mario Luca, Shah, Hetal S., Sjaarda, Jennifer, Lenzini, Petra A., Campbell, Hannah, Motsinger-Reif, Alison A., Gao, He, Lovato, Laura, Prudente, Sabrina, Pandolfi, Assunta, Pezzolesi, Marcus G., Sigal, Ronald J., Paré, Guillaume, Marcovina, Santica M., Rotroff, Daniel M., Patorno, Elisabetta, Mercuri, Luana, Trischitta, Vincenzo, Chew, Emily Y., Kraft, Peter, Buse, John B., Wagner, Michael J., Cresci, Sharon, Gerstein, Hertzel C., Ginsberg, Henry N., Mychaleckyj, Josyf C., Doria, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Genetics/Genomes/Proteomics/Metabolomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085251/
https://www.ncbi.nlm.nih.gov/pubmed/31974142
http://dx.doi.org/10.2337/db19-0973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085251/
https://www.ncbi.nlm.nih.gov/pubmed/31974142
http://dx.doi.org/10.2337/db19-0973

Ejemplares similares